Abstract
The development of macular edema in neovascular age-related macular degeneration, diabetic retinopathy, retinal vein occlusion and in many other diseases, often causes significant visual deterioration and blindness, including in people of working age. One of the methods used of treating these diseases is the intravitreal administration of anti-VEGF drugs, including ranibizumab, aflibercept, brolucizumab, etc. Faricimab is a new drug that affects both vascular endothelial growth factor and angiopoietins. In order to reduce the frequency of intravitreal injections and prolong the time of the drug effect, sustained-release devices have been developed: Port Delivery System and biodegradable drugs. Keywords: diseases of the retina, macular edema, vascular endothelial growth factor, angiopoietins, anti-VEGF drugs
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.